Endologix Receives CE Mark for ALTO Abdominal Stent Graft System
Transforming the treatment of aortic disorders, Endologix Inc. (OTC: ELGXQ) (Endologix or the Company), today announced that it has received a CE Mark for the ALTO Abdominal Stent Graft System (ALTO).
- Transforming the treatment of aortic disorders, Endologix Inc. (OTC: ELGXQ) (Endologix or the Company), today announced that it has received a CE Mark for the ALTO Abdominal Stent Graft System (ALTO).
- We are very excited to receive a CE Mark for the ALTO system, that has been achieved through a strong partnership and collaboration with our European notified body, NSAI commented Matt Thompson, Chief Medical Officer of Endologix.
- In addition, with ALTO, we anticipate observing improved short-term outcomes relative to the Ovation iX Abdominal Stent Graft System (Ovation iX) as a result of the design and manufacturing changes incorporated into ALTO.
- Lastly, CE Mark of the ALTO system is yet another critical milestone for Endologix as we seek to introduce a portfolio of devices to address the current unmet needs of endovascular aneurysm repair (EVAR).